NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

Company Overview - Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients suffering from neurohealth disorders [4] - NeuroStar Advanced Therapy is a non-drug, noninvasive treatment indicated for major depressive disorder (MDD) and is FDA-cleared for adolescents aged 15-21 with MDD [6] - NeuroStar has delivered over 6.4 million treatments, establishing itself as the leading TMS treatment for MDD in adults [6] Industry Participation - Neuronetics is participating in the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London from June 13th-15th, showcasing six posters and one oral presentation featuring data generated using the NeuroStar TMS System [4] - The company will exhibit at booth 303 during the event [4] Research Presentations - Dr. Linda Carpenter will present data on the impact of deviations in TMS treatment timing on effectiveness [2] - Dr. Paul E. Croarkin will discuss data leading to NeuroStar's latest FDA clearance for treating adolescents as a first-line adjunct treatment for MDD [2] - Dr. Harold Sackeim will explain how early improvement can predict potential responders to treatment in his presentation [5] - Dr. Hutton will identify the impact of TMS on individual symptom domains of MDD using PHQ-9 and QIDS-SR16 scales [6]